You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Effectivenss of a New Non-Invasive Erectile Support System in Aging Populations

    SBC: CONDAX, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): As a normal consequence of aging, most men experience some form of erectile dysfunction (ED), which, in severe cases, causes impotence (the inability to sustain an erection sufficient to engage and complete vaginal intercourse). Conservative estimates place the incidence of all forms of ED in the general population at 30 million cases; the percentage in the ag ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Developing a passive, non-worn, system to detect falls at home among the elderly.

    SBC: TANGIBLE DESIGN, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): Falls are the leading cause of injury death among elders in the United States and will cost the country 43B annually in 2020. Of particular concern is what is called the long lie. Over one half of elders who fallare unable to get up without assistance and they are more likely to suffer additional complications and poorer prognoses. The investigators have ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Treatment of Cytomegalovirus by Inhibition of Host Lipid Synthesis

    SBC: Kadmon Corporation, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Cytomegalovirus (CMV) causes significant disease and mortality in populations with weakened immune systems, including cancer patients, organ transplant recipients, and HIV-infected people. Additionally, it is the most common cause of congenital infection affecting about 1% of all live births worldwide, causing 20-30% of infants infected in utero to develop birt ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Rapid Assessment of Radiation Exposure

    SBC: Litron Laboratories Ltd            Topic: NIAID

    DESCRIPTION (provided by applicant): Large-scale disaster situations put considerable demands on existing medical infrastructure, as well as local governing and safety agencies. When the additional factor of ionizing radiation and exposure of humans is part of the emergency, the lack of effective assessment tools and management strategies can easily become overwhelming. As part of efforts to devis ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Human, Autologous, Pluripotent Very Small Embryonic Like (VSELs) s

    SBC: Caladrius Biosciences            Topic: NIAID

    DESCRIPTION (provided by applicant): In the event of a nuclear accident or terrorist bomb, large numbers of casualties will have been exposed to acute high-dose radiation. Those exposed will have compromised immune systems such that the virulence and infectivity of biological agents is dramatically increased. A compromised immune system exacerbates the effects of infectious agents and may preclu ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Point-of-care detection for nanoparticle-based sensors

    SBC: JUNCO LABS, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Although nanomaterials have tremendous potential to improve human health, it has remained surprisingly elusive to leverage their properties to produce real clinical impact. One of the most promising applications of nanoparticles is in sensors for detection of analytes. For sensors that need to be performed at the point of care (POC), one large barrier to unlock ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Cytokine Release Assay as a Diagnostic Test for Lyme Disease

    SBC: BIOPEPTIDES CORP            Topic: NIAID

    DESCRIPTION (provided by applicant): Lyme disease is the most common vector borne infectious disease in North America and Europe. It is a progressive disease with a wide array of clinical manifestations. Treatment of early infection is highly effective, and early diagnosis and treatment are critical to prevent disease progression. By contrast, disseminated late- phase infection is associated with ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Neutralization of ceramide as a novel approach to specifically inhibit acute GvHD

    SBC: CERAMIDE THERAPEUTICS, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Acute graft-versus-host disease (GvHD) is a primary complication of allogeneic stem cell transplantation, associated with wasting, immunosuppression and specific damage to the intestines, liver and skin. GvHD results from activation of donor T cells from human leukocyte antigen (HLA)-identical or related donors against host tissues. Current therapeutic approac ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease

    SBC: EPIVAX, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease Pompe disease is a lysosomal storage disorder caused by defects in the enzyme acid alpha-glucosidase (GAA) that leads to glycogen accumulation affectingheart and skeletal muscle. Enzyme-replacement therapy with recombinant human (rh)GAA saves the lives of children with Pompe disease. The prognos ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Retinoic Acid Modulation for Scleroderma

    SBC: Angion Biomedica Corp.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Systemic sclerosis (SSc) or diffuse scleroderma is a complex, chronic, autoimmune, connective tissue disease which primarily causes skin thickening and hardening in addition to interstitial fibrosis of lungs, gastrointestinal tract and arteries. Estimates of the prevalence of SSc in the United States (US) range from 140 to 276 patients per million (or 49,000 to ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government